GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Cyclically Adjusted PS Ratio

HROW (Harrow) Cyclically Adjusted PS Ratio : 9.49 (As of May. 30, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Harrow Cyclically Adjusted PS Ratio?

As of today (2025-05-30), Harrow's current share price is $28.0825. Harrow's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $2.96. Harrow's Cyclically Adjusted PS Ratio for today is 9.49.

The historical rank and industry rank for Harrow's Cyclically Adjusted PS Ratio or its related term are showing as below:

HROW' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.49   Med: 4.64   Max: 21.86
Current: 9.34

During the past years, Harrow's highest Cyclically Adjusted PS Ratio was 21.86. The lowest was 1.49. And the median was 4.64.

HROW's Cyclically Adjusted PS Ratio is ranked worse than
90.51% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.115 vs HROW: 9.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Harrow's adjusted revenue per share data for the three months ended in Mar. 2025 was $1.335. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.96 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Harrow Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Harrow's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Cyclically Adjusted PS Ratio Chart

Harrow Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.76 5.11 7.36 4.93 11.92

Harrow Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.63 8.38 17.07 11.92 8.98

Competitive Comparison of Harrow's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harrow's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harrow's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Harrow's Cyclically Adjusted PS Ratio falls into.


;
;

Harrow Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Harrow's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=28.0825/2.96
=9.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harrow's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Harrow's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.335/134.9266*134.9266
=1.335

Current CPI (Mar. 2025) = 134.9266.

Harrow Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.207 100.684 0.277
201509 0.279 100.392 0.375
201512 0.357 99.792 0.483
201603 0.421 100.470 0.565
201606 0.368 101.688 0.488
201609 0.361 101.861 0.478
201612 0.421 101.863 0.558
201703 0.322 102.862 0.422
201706 0.296 103.349 0.386
201709 0.320 104.136 0.415
201712 0.355 104.011 0.461
201803 0.423 105.290 0.542
201806 0.448 106.317 0.569
201809 0.495 106.507 0.627
201812 0.363 105.998 0.462
201903 0.462 107.251 0.581
201906 0.536 108.070 0.669
201909 0.499 108.329 0.622
201912 0.417 108.420 0.519
202003 0.457 108.902 0.566
202006 0.311 108.767 0.386
202009 0.532 109.815 0.654
202012 0.563 109.897 0.691
202103 0.562 111.754 0.679
202106 0.678 114.631 0.798
202109 0.690 115.734 0.804
202112 0.744 117.630 0.853
202203 0.812 121.301 0.903
202206 0.854 125.017 0.922
202209 0.834 125.227 0.899
202212 0.727 125.222 0.783
202303 0.862 127.348 0.913
202306 1.099 128.729 1.152
202309 1.000 129.860 1.039
202312 1.027 129.419 1.071
202403 0.975 131.776 0.998
202406 1.374 132.554 1.399
202409 1.380 133.029 1.400
202412 1.866 133.157 1.891
202503 1.335 134.927 1.335

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Harrow  (NAS:HROW) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Harrow Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Harrow's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Harrow Business Description

Industry
Traded in Other Exchanges
N/A
Address
1A Burton Hills Boulevard, Suite 200, Nashville, TN, USA, 37215
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Executives
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Mark L Baum director, 10 percent owner, officer: Chief Executive Officer C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Martin A. Makary director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence director 354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll officer: VP, Accounting and Reporting 437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer director, 10 percent owner, officer: Chairman of the Board 1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc other: Institutional Investor 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad other: Managing Mbr of Longboard Cap. 1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards officer: Chief Operating Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi director 2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni 10 percent owner 1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek officer: Chief Commercial Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130